Title:
ＣＤ４４標的化マルチアームコンジュゲート
Document Type and Number:
Japanese Patent JP7353378
Kind Code:
B2
Abstract:
Disclosed is a class of multi-branched drug conjugates capable of specifically targeting CD44. The class of compounds specifically binds to CD44, and may target tumor cells and tissues having high expression of CD44, so that the concentration of the conjugate in a target tissue is high, the clinical treatment effect thereof is improved, and toxicity is reduced. The compound of the present invention is suitable for treating all tumors having high expression of CD44, comprising but not limited to gastric cancer, pancreatic cancer, small cell lung cancer, colon cancer, breast cancer, lung adenocarcinoma, liver cancer, nasopharyngeal carcinoma, malignant glioma, lymphoma, renal carcinoma, ovarian cancer, head and neck cancer, squamous cell carcinoma, and the like.
Inventors:
Goken Building
Yellow and blue
Song Yunmatsu
Yellow and blue
Song Yunmatsu
Application Number:
JP2021549200A
Publication Date:
September 29, 2023
Filing Date:
February 17, 2020
Export Citation:
Assignee:
BRIGHTGENE BIO-MEDICAL TECHNOLOGY CO., LTD.
International Classes:
A61K47/66; A61P35/00
Domestic Patent References:
| JP2009539367A | ||||
| JP2017132743A | ||||
| JP2014514330A |
Foreign References:
| CN108727583A | ||||
| WO2011109678A1 | ||||
| WO2014148562A1 |
Other References:
Acta Biomaterialia,2016年,Vol.43,p.195-207
STEM CELLS,2009年,Vol.27,p.1006-1020
International Journal of Nanomedicine,2017年,Vol.12,p.2315-2333
Hepatobiliary Pancreat Dis Int,2011年,Vol.10,p.428-434
Cell Death and Disease,2013年,Vol.4, e633,p.1-13
STEM CELLS,2009年,Vol.27,p.1006-1020
International Journal of Nanomedicine,2017年,Vol.12,p.2315-2333
Hepatobiliary Pancreat Dis Int,2011年,Vol.10,p.428-434
Cell Death and Disease,2013年,Vol.4, e633,p.1-13
Attorney, Agent or Firm:
Yoshinaga Uemura
Takayoshi Kusumoto
Ryuhei Nishimura
Shindai Saito
Takayoshi Kusumoto
Ryuhei Nishimura
Shindai Saito